UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

Alimentary pharmacology & therapeutics, 2017-07, Vol.46 (2), p.150-161

2017

Volltextzugriff (PDF)

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study

British journal of dermatology (1951), 2013-08, Vol.169 (2), p.306-313

2013

Volltextzugriff (PDF)

Utilisation of anti-TNF levels in a UK tertiary IBD centre

Frontline gastroenterology, 2017-07, Vol.8 (3), p.189-195

2017

Volltextzugriff (PDF)

P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S426-S427

2020

Volltextzugriff (PDF)

P1014 Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response – Results from the FAVOUR study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1833-i1834

2024

Volltextzugriff (PDF)

PTU-065 Four-Way Comparison of Elisa Methods Available for the Measurement of Infliximab and Anti-Infliximab Antibody in IBD Patients

Gut, 2016-06, Vol.65 (Suppl 1), p.A84-A84

2016

Volltextzugriff (PDF)

P193 Validation of the two-item UC patient-reported outcome (PRO2) against the simple clinical colitis activity index (SCCAI), measures of biochemical disease activity and quality of life

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S234-S235

2020

Volltextzugriff (PDF)

PTH-090 Laboratory experience of anti-tnf drug monitoring in routine practice - perspective from the first uk centre

Gut, 2015-06, Vol.64, p.A446

2015

Volltextzugriff (PDF)

PTH-090 Laboratory experience of anti-tnf drug monitoring in routine practice – perspective from the first uk centre: Abstract PTH-090 Table 1

Gut, 2015-06, Vol.64 (Suppl 1), p.A446-A447

2015

Volltextzugriff (PDF)

PTH-091 Measurement of tnf-alpha drug levels and free versus total anti-drug antibodies using three commercially available assays

Gut, 2015-06, Vol.64, p.A447

2015

Volltextzugriff (PDF)

PTH-091 Measurement of tnf-alpha drug levels and free versus total anti-drug antibodies using three commercially available assays: Abstract PTH-091 Table 1

Gut, 2015-06, Vol.64 (Suppl 1), p.A447-A448

2015

Volltextzugriff (PDF)

PTH-053 Factors Influencing Infliximab and Adalimumab Antibody Formation and 6 Month Retrospective Follow-Up in A Tertiary IBD Centre

Gut, 2016-06, Vol.65 (Suppl 1), p.A245-A245

2016

Volltextzugriff (PDF)

PTH-074 The Presence of Total Anti-Drug Antibodies to Biologic Drugs Does not Adversely Affect Long-Term Outcomes in Crohn’s Disease Patients with Adequate Drugs Levels and Absent Free Anti-Drug Antibodies

Gut, 2016-06, Vol.65 (Suppl 1), p.A255-A256

2016

Volltextzugriff (PDF)

P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S582-S583

2020

Volltextzugriff (PDF)

P683 Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S461-S462

2019

Volltextzugriff (PDF)

PWE-109Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications

Gut, 2013-06, Vol.62 (Suppl 1), p.A175-A175

2013

Volltextzugriff (PDF)

PWE-109 Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications

Gut, 2013-06, Vol.62 (Suppl 1), p.A175

2013

Volltextzugriff (PDF)

PWE-109 Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications: Abstract PWE-109 Table

Gut, 2013-06, Vol.62 (Suppl 1), p.A175-A175

2013

Volltextzugriff (PDF)

PWE-038 Utility of measuring infliximab drug levels and anti-drug antibodies in clinical practice: a large ibd referral centre experience

Gut, 2015-06, Vol.64 (Suppl 1), p.A227-A228

2015

Volltextzugriff (PDF)

PTU-075 Utility of measuring adalimumab drug levels and anti-drug antibodies in clinical practice: a large IBD referral centre experience

Gut, 2015-06, Vol.64 (Suppl 1), p.A93-A93

2015

Volltextzugriff (PDF)

PTU-129Initial experience with infliximab levels in a tertiary IBD centre

Gut, 2012-07, Vol.61 (Suppl 2), p.A238-A238

2012

Volltextzugriff (PDF)

PTU-129 Initial experience with infliximab levels in a tertiary IBD centre

Gut, 2012-07, Vol.61 (Suppl 2), p.A238-A238

2012

Volltextzugriff (PDF)

PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice: Abstract PTH-083 Table 1

Gut, 2015-06, Vol.64 (Suppl 1), p.A443-A443

2015

Volltextzugriff (PDF)

PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice

Gut, 2015-06, Vol.64, p.A443

2015

Volltextzugriff (PDF)

Prediction of treatment response in psoriasis with measurement of serum levels of adalimumab, etanercept, and antidrug antibodies: a pilot study

The Lancet (British edition), 2013-02, Vol.381, p.S69-S69

2013

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study

Utilisation of anti-TNF levels in a UK tertiary IBD centre

P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch

P1014 Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response – Results from the FAVOUR study

PTU-065 Four-Way Comparison of Elisa Methods Available for the Measurement of Infliximab and Anti-Infliximab Antibody in IBD Patients

P193 Validation of the two-item UC patient-reported outcome (PRO2) against the simple clinical colitis activity index (SCCAI), measures of biochemical disease activity and quality of life

PTH-090 Laboratory experience of anti-tnf drug monitoring in routine practice - perspective from the first uk centre

PTH-090 Laboratory experience of anti-tnf drug monitoring in routine practice – perspective from the first uk centre: Abstract PTH-090 Table 1

PTH-091 Measurement of tnf-alpha drug levels and free versus total anti-drug antibodies using three commercially available assays

PTH-091 Measurement of tnf-alpha drug levels and free versus total anti-drug antibodies using three commercially available assays: Abstract PTH-091 Table 1

PTH-053 Factors Influencing Infliximab and Adalimumab Antibody Formation and 6 Month Retrospective Follow-Up in A Tertiary IBD Centre

PTH-074 The Presence of Total Anti-Drug Antibodies to Biologic Drugs Does not Adversely Affect Long-Term Outcomes in Crohn’s Disease Patients with Adequate Drugs Levels and Absent Free Anti-Drug Antibodies

P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study

P683 Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study

PWE-109Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications

PWE-109 Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications

PWE-109 Measurement of Infliximab and Anti-Infliximab Antibodies - Analytical Aspects and Clinical Implications: Abstract PWE-109 Table

PWE-038 Utility of measuring infliximab drug levels and anti-drug antibodies in clinical practice: a large ibd referral centre experience

PTU-075 Utility of measuring adalimumab drug levels and anti-drug antibodies in clinical practice: a large IBD referral centre experience

PTU-129Initial experience with infliximab levels in a tertiary IBD centre

PTU-129 Initial experience with infliximab levels in a tertiary IBD centre

PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice: Abstract PTH-083 Table 1

PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice

Prediction of treatment response in psoriasis with measurement of serum levels of adalimumab, etanercept, and antidrug antibodies: a pilot study

Suchergebnisse filtern